Pharmacogenetic aspects of bipolar disorder

Pharmacogenomics

Volumn 4, Issue 1, 2003, Pages 35-40

  Alda, Martin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Genetic factors; Lithium; Mania; Pharmacogenetics

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN TRANSPORTER; TOPIRAMATE; TRYPTOPHAN HYDROXYLASE; VALPROIC ACID;

ACCURACY; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; GENE MAPPING; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; MANIA; PATIENT COMPLIANCE; PHARMACOGENETICS; PHENOTYPE; REVIEW;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CHROMOSOME MAPPING; HUMANS; LITHIUM; PHARMACOGENETICS;

EID: 0037236153     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.1.35.22584     Document Type: Review

References (55)

1. Osby U, Brandt L, Correia N et al.: Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58, 844-850 (2001).
2. Young LT, Joffe RT, Robb JC et al.: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry 157, 124-126 (2000).
3. Baldessarini RJ, Tondo L: Does lithium treatment still work? Evidence of stable responses over three decades. Arch. Gen. Psychiatry 57, 187-190 (2000).
4. Lerer B: Alternative therapies for bipolar disorder. J Clin. Pychiatry 46, 309-316 (1985).
5. Nemeroff CB: An ever-increasing Pharmacopeia for the management of patients with bipolar disorder. J. Clin. Psychiatry 61 Suppl. 13, 19-25 (2000).
6. Licht RW, Qvitzau S: Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Pychopharmacology (Berl.) 161, 143-151 (2002).
7. Schmidt ME, Fava M, Zhang S et al.: Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychotherapy Psychosomatics 71, 190-194 (2002).
8. Gelenberg AJ, Kane JM, Keller MB et al.: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J Med. 321, 1489-1493 (1989).
9. Walsh BT, Seidman SN, Sysko R et al.: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287, 1840-1847 (2002).
10. Mendlewicz; J, Fieve RR, Stallone F: Relationship between the effectiveness of lithium therapy and family history. Am. J. Pychiatry 130, 1011-1013 (1973).
11. Prien RF, Caffey EM, Klett CJ: Factors associated with treatment success in lithium carbonate prophylaxis: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch. Gen. Psychiatry 31, 189-192 (1974).
12. Zvolsky P, Vinarova E, Dostal T et al.: Family history of manic-depressive and endogenous depresive patients and clinical effect of treatment with lithium. Activitas Nervosa Superior 16, 194-195 (1974).
13. Maj M, Del Vecchio M, Starace F et al.: Prediction of affective psychoses response to lithium prophylaxis: the role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatrica Scandinavica 69, 37-44 (1984).
14. Smeraldi E, Petroccione A, Gasperini M et al.: Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J. Affective Disorders 6, 139-151 (1984).
15. Grof P. Alda M, Grof E et al.: Lithium response and genetics of affective disorders. J. Affective Disorders 32, 85-95 (1994).
16. Engstrom C, Astrom M, Nordqvist-Karlsson B et al.: Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol. Psychiatry 42, 425-433 (1997).
17. Coryell W, Akiskal H, Leon AC et al.: Family history and symptom levels during treatment for bipolar I affective disorder. Biol. Psychiatry 47, 1034-1042 (2000).
18. Alda M: Genetic factors and treatment of mood disorders. Bipolar Disorders 3, 318-324 (2001).
19. Angst J: A clinical analysis of the effects of tofranil in depression: longitudinal and follow-up studies. Treatment of blood-relations, Psychopharmacologia 2, 381-407 (1961).
20. Pare CM, Rees L, Sainsbury MJ: Differentiation of two genetically specific types of depression by the response to antidepressants. Lancet 29, 1340-1343 (1962).
21. Pare CMB, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J. Med. Genetics 8, 306-309 (1971).
22. O'Reilly RL, Bogue L, Singh SM: Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol, Psychiatry 36, 467-471 (1994).
23. Franchini L, Serretti A, Gasperini M et al.: Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J. Psychiatric Res. 32, 255-259 (1998).
24. Grof P, Duffy A, Cavazzoni P et al.: Is response to prophylactic lithium a familial trait? J. Clin. Psychiatry 63, 942-947 (2002).
25. Grof P, Alda M, Grof E et al.: The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br. J Psychiatry 163, Suppl. 21, 16-19 (1993).
26. Alda M, Passmore M, Garnham J et al.: Clinical presentation of bipolar disorders responsive to lithium or lamotrigine. Int. J Neuropsychopharmacol. 5, S58 (2002).
27. Coppen A, Montgomery SA, Gupta RK et al.: A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br. J. Psychiatry 128, 79-85 (1976).
28. Serretti A, Lilli R, Lorenzi C et al.: Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int. J. Neuropsychopharmacol. 1, 125-129 (1998).
29. Steen VM, Lovlie R, Osher Y et al.: The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 8, 259-268 (1998).
30. Del Zompo M, Ardau R, Palmas MA et al.: Lithium response: association study with two candidate genes. Mol, Psychiatry 4, 66-67 (1999).
31. Serretti A, Lilli R, Lorenzi C et al: Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J. Pychiatric Res. 33, 371-377 (1999).
32. Lovlie R, Berle JO, Steen VM: A role of the human inositol polyphosphate 1-phosphatase gene (INPP1) in lithium-treated bipolar disorder? Mol. Psychiatry 4, Suppl. 1, S68 (1999).
33. Serretti A, Lilli R, Lorenzi C et al.: Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 87, 7-19 (1999).
34. Serretti A, Lorenzi C, Lilli R et al.: Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J. Psychiatric Res. 34, 89-98 (2000).
35. Serretti A, Lilli R, Mandelli L et al.: Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 1, 71-77 (2001).
36. Lovlie R, Berle JO, Stordal E et al.: The phospholipase C-gammal gene (PLCG1) and lithium-responsive bipolar disorder: reexamination of an intronic dinucleotide repeat polymorphism. Psychiatric Genetics 11, 41-44 (2001).
37. Serretti A, Lorenzi C, Lilli R et al.: Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAOA, and Gbeta3 variants. Am. J. Med. Genetics (Neuropsychiatric Genetics) 114, 370-379 (2002).
38. Heils A, Teufel A, Petri S et al: Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66, 2621-2624 (1996).
39. Mundo E, Walker M, Cate T et al.: The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch. Gen. Psychiatry 58, 539-544 (2001).
40. Serretti A, Artioli P, Lattuada E et al.: Antidepressant induced mania in bipolar disorder: clinical and genetic descriptors. Int. J. Neuropsychopharmacol. 5, Suppl. 1, S55 (2002).
41. Duffy A, Grof P, Grof E et al.: Evidence supporting the independent inheritance of primary affective disorders and primary alcoholism in the families of bipolar patients. J. Affective Disorders 50, 91-96 (1998).
42. Duffy A, Alda M, Kutcher S et al.: Psychiatric symptoms and syndromes among adolescent children of parents with lithium-responsive or lithium-nonresponsive bipolar disorder. Am. J Psychiatry 155, 431-433 (1998).
43. Alda M, Grof P, Grof E et al.: Mode of inheritance in families of patients with lithium - responsive affective disorders. Acta Pychiatrica Scandinavica 90, 304-310 (1994).
44. Alda M, Grof E, Cavazzoni P et al.: Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? J. Affective Disorders 44, 153-157 (1997).
45. Cavazzoni P, Alda M, Turecki G et al.: Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res. 64, 91-96 (1996).
46. Turecki G, Alda M, Grof P et al.: No association between chromosome-18 markers and lithium responsive affective disorders. Psychiatry Res. 63, 17-23 (1996).
47. Turecki G, Grof P, Cavazzoni P et al.: Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol. Psychiatry 3, 534-538 (1998).
48. Turecki G, Alda M, Grof P et al.: Expanded polyglutamine tracts: No evidence of a major role in bipolar disorder. Mol. Psychiatry 4, 220-222 (1999).
49. Turecki G, Grof P. Cavazzoni P et al.: MAOA; association and linkage studies with lithium responsive bipolar disorder. Psychiatric Genetics 9, 13-16 (1999).
50. Turecki G, Grof P, Cavazzoni P et al.: Lithium responsive bipolar disorder, unilineality, and chromosome 18: A linkage study. Am. J. Med. Genetics (Neuropsychiatric Genetics) 88, 411-415 (1999).
51. Alda M, Turecki G, Grof P et al.: Association and linkage analyses of CRH and PENK genes in bipolar disorder responsive to lithium: a collaborative IGSLi study. Am. J. Med. Genetics (Neuropsychiatric Genetics) 96, 178-181 (2000).
52. Duffy A, Turecki G, Grof P et al.: Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium responsive bipolar disorder. J. Psychiatry Neurosci. 25, 353-358 (2000).
53. Turecki G, Alda M, Grof P et al.: Polyglutamine, coding genes in bipolar disorder. Lack of association with selected candidate loci. J Affective Disorders 53, 63-68 (2000).
54. Ftouhi-Paquin N, Alda M, Grof P et al.: Identification of three polymorphisms in the translated region of PLC-1 and their investigation in lithium responsive bipolar disorder. Am. J. Med. Genetics (Neuropsychiatric Genetics) 105, 301-305 (2001).
55. Turecki G, Grof P, Grof E et al.: Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 6, 570-578 (2001).